• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 2008 ASH_Anti-AML Activity of SGI-110 and SGI-1036, panobinostat Combined...

2008 ASH_Anti-AML Activity of SGI-110 and SGI-1036, panobinostat Combined Therapy

25 November 2008/in Uncategorised

2008 ASH_Anti-AML Activity of SGI-110 and SGI-1036, panobinostat Combined Therapy

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2008-11-25 16:04:512016-12-01 12:33:032008 ASH_Anti-AML Activity of SGI-110 and SGI-1036, panobinostat Combined Therapy

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: 2008 EORTC_In Vivo Activity of SGI-110, a Novel Hypomethylating Agent Link to: 2008 EORTC_In Vivo Activity of SGI-110, a Novel Hypomethylating Agent 2008 EORTC_In Vivo Activity of SGI-110, a Novel Hypomethylating Agent Link to: 2008 ASH_Anti-AML Activity of SGI-110 and SGI-1036, panobinostat Combined Therapy Link to: 2008 ASH_Anti-AML Activity of SGI-110 and SGI-1036, panobinostat Combined Therapy 2008 ASH_Anti-AML Activity of SGI-110 and SGI-1036, panobinostat Combined T...
Scroll to top Scroll to top Scroll to top